Inhibikase Therapeutics (NASDAQ:IKT) Upgraded at Cantor Fitzgerald

Cantor Fitzgerald upgraded shares of Inhibikase Therapeutics (NASDAQ:IKT) to a strong-buy rating in a report released on Thursday,Zacks.com reports.

Other analysts have also issued reports about the stock. Lifesci Capital upgraded shares of Inhibikase Therapeutics to a “strong-buy” rating in a research report on Monday, December 1st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inhibikase Therapeutics in a research note on Wednesday, October 8th. Wall Street Zen raised Inhibikase Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, September 20th. Finally, Zacks Research upgraded Inhibikase Therapeutics to a “hold” rating in a research report on Tuesday, December 2nd. Two analysts have rated the stock with a Strong Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy”.

Inhibikase Therapeutics Price Performance

Inhibikase Therapeutics stock opened at $1.54 on Thursday. Inhibikase Therapeutics has a fifty-two week low of $1.33 and a fifty-two week high of $4.20. The firm has a fifty day moving average price of $1.55. The firm has a market capitalization of $115.77 million, a price-to-earnings ratio of -3.95 and a beta of 0.88.

Inhibikase Therapeutics (NASDAQ:IKT) last issued its quarterly earnings data on Friday, November 14th. The company reported ($0.13) EPS for the quarter.

Inhibikase Therapeutics Company Profile

Inhibikase Therapeutics, Inc, a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers.